Inhibition of IL-6-dependent growth of myeloma cells by an acidic peptide repressing the gp130-mediated activation of Src family kinases

Oncogene

Volumn 26, Issue 34, 2007, Pages 4987-4998

  Hausherr, A ^a   Tavares, R ^a   Schaffer M ^b,c   Obermeier, A ^b   Miksch, C ^b   Mitina, O ^a   Ellwart, J ^a   Hallek, M ^a,d   Krause, G ^a,d  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b Sireen AG   (Germany)

^c CRELUX GmbH   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

gp130; Interleukin 6 signalling; Membrane permeant peptide; Myeloma; Src family kinases

Indexed keywords

CHIMERIC PROTEIN; ERYTHROPOIETIN; GLYCOPROTEIN GP 130; HEMATOPOIETIC CELL KINASE; INTERLEUKIN 6; MUTANT PROTEIN; PROTEIN KINASE FYN; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE; RETROVIRUS VECTOR; STAT3 PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL COUNT; CELL TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE REPRESSION; GENE SEQUENCE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYBRIDOMA CELL CULTURE; IC 50; IMMUNOPRECIPITATION; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; MYRISTYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; BIOLOGICAL TRANSPORT; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINE RECEPTOR GP130; HUMANS; INTERLEUKIN-6; MICE; MOLECULAR SEQUENCE DATA; MULTIPLE MYELOMA; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-HCK; SRC-FAMILY KINASES; STAT3 TRANSCRIPTION FACTOR;

EID: 34547442420     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210306     Document Type: Article

References (44)

1. Adachi T, Pazdrak K, Stafford S, Alam R. (1999a). The mapping of the Lyn kinase binding site of the common β: subunit of IL-3/granulocyte-macrophage colony stimulation factor/IL-5 receptor. J Immunol 162: 1496-1501.
2. Adachi T, Stafford S, Sur S, Alam R. (1999b). A novel Lyn-binding peptide inhibitor blocks eosinophil differentiation, survival, and airway eosinophilic inflammation. J Immunol 163: 939-946.
3. Ancey C, Kuster A, Haan S, Herrmann A, Heinrich PC, Muller-Newen G. (2003). A fusion protein of the gp130 and interleukin-6Ralpha ligand-binding domains acts as a potent interleukin-6 inhibitor. J Biol Chem 278: 16968-16972.
4. Boehning D, van Rossum DB, Patterson RL, Snyder SH. (2005). A peptide inhibitor of cytochrome c/inositol 1, 4, 5-trisphosphate receptor binding blocks intrinsic and extrinsic cell death pathways. Proc Natl Acad Sci USA 102: 1466-1471.
5. Brocke-Heidrich K, Kretzschmar AK, Pfeifer G, Henze C, Loffler D, Koczan D et al. (2004). Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation. Blood 103: 242-251.
6. Burger R, Guenther A, Bakker F, Schmalzing M, Bernand S, Baum W et al. (2001). Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematol J 2: 42-53.
7. Chatterjee M, Honemann D, Lentzsch S, Bommert K, Sers C, Herrmann P et al. (2002). In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood 100: 3311-3318.
8. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L et al. (2005). Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 115: 369-378.
9. Cote S, Simard C, Lemieux R. (2002). Regulation of growth-related genes by interleukin-6 in murine myeloma cells. Cytokine 20: 113-120.
10. Covic L, Gresser AL, Talavera J, Swift S, Kuliopulos A. (2002). Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci USA 99: 643-648.
11. Dasgupta P, Singh AT, Mukherjee R. (2000). Lipophilization of somatostatin analog RC-160 with long chain fatty acid improves its anti-proliferative activity on human oral carcinoma cells in vitro. Life Sci 66: 1557-1570.
12. Eichholtz T, de Bont DB, de Widt J, Liskamp RM, Ploegh HL. (1993). A myristoylated pseudosubstrate peptide, a novel protein kinase C inhibitor. J Biol Chem 268: 1982-1986.
13. Ernst M, Gearing DP, Dunn AR. (1994). Functional and biochemical association of Hck with the LIF/IL-6 receptor signal transducing subunit gp130 in embryonic stem cells. EMBO J 13: 1574-1584.
14. Ernst M, Jenkins BJ. (2004). Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet 20: 23-32.
15. French JD, Tschumper RC, Jelinek DF. (2000). Dissection of the signalling requirements of interleukin-6-stimulated myeloma cell growth. Acta Oncol 39: 777-781.
16. Georgii-Hemming P, Stromberg T, Janson ET, Stridsberg M, Wiklund HJ, Nilsson K. (1999). The somatostatin analog octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines. Blood 93: 1724-1731.
17. Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T et al. (2003). Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol 31: 271-282.
18. Hallek M, Bergsagel LP, Anderson KC. (1998). Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91: 3-21.
19. Hallek M, Neumann C, Schaffer M, Danhauser-Riedl S, von Bubnoff N, de Vos G et al. (1997). Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines. Exp Hematol 25: 1367-1377.
20. Hatakeyama M, Kono T, Kobayashi N, Kawahara A, Levin SD, Perlmutter RM et al. (1991). Interaction of the IL-2 receptor with the src-family kinase p56lck: identification of novel intermolecular association. Science 252: 1523-1528.
21. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. (2003). Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1-20.
22. Hideshima T, Anderson K. (2002). Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2: 927-937.
23. Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D et al. (2004). Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 36: 453-461.
24. Ihle JN. (1996). STATs: signal transducers and activators of transcription. Cell 84: 331-334.
25. Ishihara K, Hirano T. (2002). IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 13: 357-368.
26. Kardinal C, Konkol B, Schulz A, Posern G, Lin H, Adermann K et al. (2000). Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients. FASEB J 14: 1529-1538.
27. Kelemen BR, Hsiao K, Goueli SA. (2002). Selective in vivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides. J Biol Chem 277: 8741-8748.
28. LaFevre-Bernt M, Sicheri F, Pico A, Porter M, Kuriyan J, Miller WT. (1998). Intramolecular regulatory interactions in the Src family kinase Hck probed by mutagenesis of a conserved tryptophan residue. J Biol Chem 273: 32129-32134.
29. Laszlo GS, Nathanson NM. (2003). Src family kinase-independent signal transduction and gene induction by leukemia inhibitory factor. J Biol Chem 278: 27750-27757.
30. Manfredini R, Tenedini E, Siena M, Tagliafico E, Montanari M, Grande A et al. (2003). Development of an IL-6 antagonist peptide that induces apoptosis in 7TD1 cells. Peptides 24: 1207-1220.
31. Neumann C, Zehentmaier G, Danhauser-Riedl S, Emmerich B, Hallek M. (1996). Interleukin-6 induces tyrosine phosphorylation of the Ras activating protein Shc, and its complex formation with Grb2 in the human multiple myeloma cell line LP-1. Eur J Immunol 26: 379-384.
32. Niv MY, Rubin H, Cohen J, Tsirulnikov L, Licht T, Peretzman-Shemer A et al. (2004). Sequence-based design of kinase inhibitors applicable for therapeutics and target identification. J Biol Chem 279: 1242-1255.
33. Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL et al. (1997). IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 159: 2212-2221.
34. Ohtani T, Ishihara K, Atsumi T, Nishida K, Miyata T, Itoh S et al. (2000). Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3- and SHP2-mediated signals in immune responses. Immunity 12: 95-105.
35. Podar K, Mostoslavsky G, Sattler M, Tai YT, Hayashi T, Catley LP et al. (2004). Critical role for Hck-mediated phosphorylation of Gab1 and Gab2 docking proteins in IL-6- induced proliferation and survival of MM cells. J Biol Chem 279: 21658-21665.
36. Podar K, Tai YT, Cole CE, Hideshima T, Sattler M, Hamblin A et al. (2003). Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem 278: 5794-5801.
37. Posern G, Zheng J, Knudsen BS, Kardinal C, Muller KB, Voss J et al. (1998). Development of highly selective SH3 binding peptides for Crk and CRKL which disrupt Crk-complexes with DOCK180, SoS and C3G. Oncogene 16: 1903-1912.
38. Schaeffer M, Schneiderbauer M, Weidler S, Tavares R, Warmuth M, de Vos G et al. (2001). Signalling through a novel domain of gp130 mediates cell proliferation and activation of Hck and Erk kinases. Mol Cell Biol 21: 8068-8081.
39. Schulze WX, Mann M. (2004). A novel proteomic screen for peptide-protein interactions. J Biol Chem 279: 10756-10764.
40. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. (2004). Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401.
41. Stahl N, Farugella TJ, Boulton TG, Ip NY, Davis S, Witthuhn BA et al. (1994). Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 β receptor components. Science 263: 92-95.
42. Trikha M, Corringham R, Klein B, Rossi JF. (2003). Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a reviewof the rationale and clinical evidence. Clin Cancer Res 9: 4653-4665.
43. Warmuth M, Bergmann M, Priess A, Hauslmann K, Emmerich B, Hallek M. (1997). The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem 272: 33260-33270.
44. Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley PW et al. (2003). Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 101: 664-672.